This immunohistochemical assay in other tumour types (i.e. lung and urothelial) can identify patients more likely to benefit from treatment with anti-PD-L1 immunotherapy such as durvalumab, pembrolizumab and nivolumab. Here, CD274 is linked to neoplasm.